CD4 and rheumatoid arthritis: To further characterize the significance of IL-22 and IL22+CD4+T cells in RA, particularly in the treatment response of RA patients to DMARDs, we carried out a prospective study and monitored the levels of circulating IL-22-producing Th cells and the plasma IL-22 level in RA patients following treatment with combination MTX+LEF therapy.